Back to top
more

VolitionRX Limited (VNRX)

(Delayed Data from AMEX)

$0.62 USD

0.62
133,937

-0.06 (-8.66%)

Updated Apr 16, 2024 03:51 PM ET

After-Market: $0.62 0.00 (0.00%) 5:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

VolitionRX Limited [VNRX]

Reports for Purchase

Showing records 1 - 20 ( 100 total )

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 1

02/08/2024

Company Report

Pages: 12

Snaring sepsis, with early NETs detection

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 25.00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 2

01/17/2023

Company Report

Pages: 10

Vetting the pet health opportunity

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 3

08/15/2022

Daily Note

Pages: 10

Unravelling the web of NETs in sepsis

Provider: Edison Investment Research Limited

Analyst: ROMANOFF S

Price: 12.50

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 4

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for VNRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 5

08/17/2020

Company Report

Pages: 18

Provider: Zacks Investment Research

Analyst: RALSTON S

Price: 24.95

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 6

02/28/2020

Company Report

Pages: 5

New platform format; more proof-of-concept data

Provider: Edison Investment Research Limited

Analyst: PECIULIS J

Price: .00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 7

11/22/2019

Company Report

Pages: 6

Data with product-grade assays expected soon

Provider: Edison Investment Research Limited

Analyst: PECIULIS J

Price: .00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 8

08/21/2019

Company Report

Pages: 6

Nu.Q lung cancer test development accelerates

Provider: Edison Investment Research Limited

Analyst: PECIULIS J

Price: .00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 9

05/21/2019

Company Report

Pages: 13

Price: 24.95

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 10

05/14/2019

Company Report

Pages: 16

Multiple partnerships enable diversification

Provider: Edison Investment Research Limited

Analyst: PECIULIS J

Price: .00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 11

04/24/2019

Company Report

Pages: 6

Price: 24.95

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 12

03/20/2019

Company Report

Pages: 12

Price: 24.95

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 13

11/29/2018

Company Report

Pages: 6

Platform upgrades and busy 2019

Provider: Edison Investment Research Limited

Analyst: PECIULIS J

Price: .00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 14

11/20/2018

Company Report

Pages: 14

Price: 24.95

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 15

08/28/2018

Company Report

Pages: 14

Price: 24.95

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 16

07/18/2018

Company Report

Pages: 8

Shifts in US CRC screening; major catalysts in H2

Provider: Edison Investment Research Limited

Analyst: PECIULIS J

Price: .00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 17

06/04/2018

Company Report

Pages: 9

(3Q18) and establishing a final panel for the Nu.Q Colorectal Cancer Frontline Screening Test.

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 25.00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 18

05/18/2018

Company Report

Pages: 13

Price: 24.95

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 19

04/21/2018

Company Report

Pages: 5

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: VolitionRX Limited

Industry: Medical - Biomedical and Genetics

Record: 20

03/20/2018

Company Report

Pages: 9

VolitionRX Ltd. has made significant progress since our last note on both clinical and corporate fronts, as highlighted below.

Provider: SEETHRUEQUITY, LLC

Analyst: TANDON A

Price: 25.00

Research Provided by a Third Party